As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) will provide much needed research space to develop therapies, vaccines and diagnostic tests for naturally occurring emerging diseases such as SARS, West Nile encephalitis and avian flu, as well as for microbes that might be employed by terrorists.
- Facility size: 186,267 gross square feet
- Total laboratory space: 47,826 net square feet
- Total BSL4 space: 12,222 net square feet
- Total project cost: $174 million
- Federal grant amount: $115 million
- State of Texas Match: $57 million
- Philanthropy: $1.6 million
- Projected economic impact: $1.4 billion over 20 years statewide
- Construction start date: May 2005
- Substantial completion date: July/August 2008
- Move-in date: October 2008
- Facility dedication date: November 11, 2008
- Ownership: UTMB will own and operate the GNL; NIAID and other federal agencies, foundations and industry will support the research projects inside it.
- Types of pathogens to be studied: Anthrax, avian influenza, bubonic plague, hemorrhagic fevers (such as Ebola), typhus, West Nile virus, influenza, drug-resistant tuberculosis and others.
For more information, contact us at email@example.com.